Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 1.00 |
| ▸ | SRC | P12931 | 9/20 | 1.00 |
| ▸ | VCP | P55072 | 1/20 | 0.89 |
| ▸ | EGFR | P00533 | 13/20 | 0.83 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.83 |
| ▸ | BTK | Q06187 | 2/20 | 0.78 |
| ▸ | BLK | P51451 | 1/20 | 0.78 |
| ▸ | BMX | P51813 | 1/20 | 0.78 |
| ▸ | JAK3 | P52333 | 1/20 | 0.78 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060509 | 1.00 | FYN (1.00) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL7239048 | 0.92 | FYN (0.85) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL7239977 | 0.91 | EGFR (1.00) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL5928094 | 0.90 | SRC (0.82) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL2680536 | 0.88 | EGFR (1.00) | FYNSRCEGFRERBB2BTK | |
| SCHEMBL2991796 | 0.88 | EGFR (1.00) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL29359583 | 0.88 | EGFR (1.00) | FYNSRCEGFRERBB2BTK | |
| SCHEMBL7914891 | 0.88 | FYN (0.78) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL3241277 | 0.88 | FYN (0.78) | FYNSRCVCPEGFRERBB2 | |
| SCHEMBL2986894 | 0.88 | EGFR (1.00) | FYNSRCVCPEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10640524-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMNT, LTD (CY) | 2020-05-05 | — | — | US | disclosed |
| EP-3108900-B1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS IASIS RES AND DEVELOPMENT LTD (CY) | 2019-04-24 | — | — | EP | disclosed |
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2018-06-21 | — | — | US | disclosed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
| EP-3108900-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-Iasis Research and Development, Ltd (CY) | 2016-12-28 | — | — | EP | disclosed |
| EP-1379686-B1 | METHOD OF DETERMINING EPIDERMAL GROWTH FACTOR RECEPTOR AND HER2-NEU GENE EXPRESSION AND CORRELATION OF LEVELS THEREOF WITH SURVIVAL RATES | RESPONSE GENETICS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012097368-A2 | HER3 AND HER4 PRIMERS AND PROBES FOR DETECTING HER3 AND HER4 MRNA EXPRESSION | RESPONSE GENETICS, INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120040346-A1 | Method of Determining Chemotherapy of Metastatic Tumor by Assaying DPD Gene Expression in Primary Tumors | DANENBERG KATHLEEN D (US) | 2012-02-16 | — | — | US | disclosed |
| CN-102220414-A | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates | RESPONSE GENETICS INC | 2011-10-19 | — | — | CN | disclosed |
| EP-1411993-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-04-28 | — | — | EP | disclosed |
| CN-1488002-A | Method for determining epidermal growth factor receptor and HER 2-neu gene expression and correlation between levels and survival rates | ��˹��ŵ�� | 2004-04-07 | — | — | CN | disclosed |
| EP-1379686-A2 | METHOD OF DETERMINING EPIDERMAL GROWTH FACTOR RECEPTOR AND HER2-NEU GENE EXPRESSION AND CORRELATION OF LEVELS THEREOF WITH SURVIVAL RATES | Response Genetics, Inc. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030211530-A1 | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates | DANENBERG KATHLEEN D (US) | 2003-11-13 | — | — | US | disclosed |
| US-6582919-B2 | Obtaining a tissue sample of the tumor and non-malignant tissue; isolating mRNA; amplification using primers; determining the amount of HER2-neu mRNA; obtaining a differential HER2-neu epression level; determining | RESPONSE GENETICS, INC. | 2003-06-24 | — | — | US | disclosed |
| US-20020192652-A1 | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates | CANCER GENETICS, INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020142328-A1 | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors | RESPONSE GENETICS, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002073235-A2 | RADIOLABELED IRREVERSIBLE INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE AND THEIR USE IN RADIOIMAGING AND RADIOTHERAPY | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002044423-A2 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BY ASSAYING GENE EXPRESSION IN PRIMARY TUMORS | RESPONSE GENETICS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044413-A2 | METHOD OF DETERMINING EPIDERMAL GROWTH FACTOR RECEPTOR AND HER2-NEU GENE EXPRESSION AND CORRELATION OF LEVELS THEREOF WITH SURVIVAL RATES | RESPONSE GENETICS, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640524-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | TP53, MKI67, FLT3 | FYN 1145/4885SRC 188/4885VCP 4800/4885 |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | FYN 1145/4885SRC 188/4885VCP 4800/4885 |
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | FYN 1145/4885SRC 188/4885VCP 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.